| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8657013 | Atherosclerosis | 2018 | 7 Pages |
Abstract
Administration of PCSK9 antibody significantly alters the lipid composition of plasma and lipoprotein particles. These changes further shed light on the link between anti-PCSK9 therapies and cardiovascular risk.
Keywords
LacCerGb3GOFPCSK9HDL-CLPCLDL-CLOFAtherosclerosisLoss-of-functionsphingolipidssphingomyelincoronary artery diseasetriacylglycerolTAG یا triacylglycerols triglycerideDrug therapydiacylglycerolDAGCerceramidegain-of-functionCADphosphatidylinositolphosphatidylcholinephosphatidylethanolaminelactosylceramideLysophosphatidylcholineLipoproteinsLipidomicsHDL-cholesterolLDL-cholesterolcholesteryl estertotal cholesterol
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mika Hilvo, Helena Simolin, Jari Metso, Maija Ruuth, Katariina Ãörni, Matti Jauhiainen, Reijo Laaksonen, Amos Baruch,